Wang Wenjie, Chen Jingdi, Zhan Liying, Zou Handong, Wang Lu, Guo Mengmeng, Gao Hang, Xu Jing, Wu Wei
Department of Thoracic Surgery, Renmin Hospital of Wuhan University, Wuhan, Hubei, China.
Department of orthopedics, The Airborne Military Hospital, Wuhan, Hubei, China.
Front Immunol. 2025 Feb 5;16:1531577. doi: 10.3389/fimmu.2025.1531577. eCollection 2025.
Maintaining iron homeostasis is necessary for kidney functioning. There is more and more research indicating that kidney disease is often caused by iron imbalance. Over the past decade, ferroptosis' role in mediating the development and progression of renal disorders, such as acute kidney injury (renal ischemia-reperfusion injury, drug-induced acute kidney injury, severe acute pancreatitis induced acute kidney injury and sepsis-associated acute kidney injury), chronic kidney disease (diabetic nephropathy, renal fibrosis, autosomal dominant polycystic kidney disease) and renal cell carcinoma, has come into focus. Thus, knowing kidney iron metabolism and ferroptosis regulation may enhance disease therapy. In this review, we discuss the metabolic and molecular mechanisms of iron signaling and ferroptosis in kidney disease. We also explore the possible targets of ferroptosis in the therapy of renal illness, as well as their existing limitations and future strategies.
维持铁稳态对肾脏功能至关重要。越来越多的研究表明,肾脏疾病常由铁失衡引起。在过去十年中,铁死亡在介导肾脏疾病(如急性肾损伤,包括肾缺血再灌注损伤、药物性急性肾损伤、重症急性胰腺炎诱导的急性肾损伤和脓毒症相关性急性肾损伤)、慢性肾脏病(糖尿病肾病、肾纤维化、常染色体显性多囊肾病)和肾细胞癌的发生发展中的作用已成为焦点。因此,了解肾脏铁代谢和铁死亡调节可能会改善疾病治疗。在这篇综述中,我们讨论了肾脏疾病中铁信号传导和铁死亡的代谢及分子机制。我们还探讨了铁死亡在肾脏疾病治疗中的可能靶点,以及它们目前的局限性和未来策略。
Front Immunol. 2025-2-5
J Drug Target. 2024-8
Front Immunol. 2024
Nat Rev Cardiol. 2023-1
Int J Nanomedicine. 2025-2-5
Clin Exp Nephrol. 2024-9
Int Urol Nephrol. 2019-11-25
J Mol Med (Berl). 2025-9-3
Front Cell Dev Biol. 2025-6-30
Front Cell Dev Biol. 2025-6-25
Oxid Med Cell Longev. 2022
J Cell Physiol. 2022-12
Front Mol Biosci. 2022-8-24
Cochrane Database Syst Rev. 2022-8-25